DifGen Pharmaceuticals has received approval from the FDA for its Fluorometholone Ophthalmic Suspension, 0.1% - a complex generic formulation used to treat eye inflammation. This is only the second generic USFDA approval of this complex suspension product.
"We are extremely proud that we received this first cycle approval, which marks a significant milestone for DifGen, demonstrating our expertise in developing complex ophthalmic suspension products with a high regulatory threshold for demonstration of therapeutic equivalence," said Ramandeep Singh Jaj & Santhanakrishnan Srinivasan, Founders & Co-CEO's DifGen Pharmaceuticals. "Our team has worked tirelessly to bring this challenging product to market, and their dedication reflects our commitment to enhancing patient access to essential treatments. This achievement highlights the importance of DifGen Pharmaceuticals in delivering innovative solutions for critical health needs."
Fluorometholone Ophthalmic Suspension is a corticosteroid indicated for treating steroid-responsive inflammatory conditions of the eye's anterior segment.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!